Section Arrow
ABIO.NASDAQ
- ARCA biopharma
Quotes are at least 15-min delayed:2024/04/29 14:52 EDT
Last
 3.48
-0.1 (-2.79%)
Day High 
3.6 
Prev. Close
3.58 
1-M High
3.88 
Volume 
188.14K 
Bid
3.46
Ask
3.48
Day Low
3.42 
Open
3.57 
1-M Low
1.69 
Market Cap 
51.91M 
Currency USD 
P/E -- 
%Yield
10-SMA 3.41 
20-SMA 3.14 
50-SMA 2.27 
52-W High 3.88 
52-W Low 1.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.37/-8.80
Enterprise Value
52.12M
Balance Sheet
Book Value Per Share
2.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings1.005+0.1449+16.85%-- 
JAGXJaguar Health0.1969+0.0169+9.39%-- 
IBRXImmunityBio9.0201+1.6701+22.72%-- 
XFORX4 Pharmaceuticals1.175+0.01+0.86%-- 
GERNGeron Corp4.19+0.4+10.55%-- 
Quotes are at least 15-min delayed:2024/04/29 14:52 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.